Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Tele2 launches new LTE-M network for IoT

Tele2 IoT launches a new LTE-M network, the technology specifically designed for the Internet of Things (IoT).Tele2 is pleased to announce the launch of its new LTE-M network. LTE-M is a technology that greatly enhances Tele2’s offering in managed IoT connectivity, with a dedicated radio access technology designed for massive IoT applications.   As a cellular LPWA (low-power, wide area) technology, LTE-M brings seamless connectivity, supports lower cost devices and longer battery life and enables many new IoT use cases. LTE-M also supports existing IoT use cases previously based on 2G or

Nokian Tyres made a world record possible: Car pushing is a game of skill, not brute force

A new Guinness World Record  for the fastest time to push a car one mile (1.6 km) has been set in Finland. The record was set by Jussi Kallioniemi, who says that this is not a test of brute force but rather an enormous puzzle. A key piece of the performance were the lightly rolling Nokian Hakkapeliitta R3 SUV winter tires  and their extremely light rolling resistance. 13 minutes and 26 seconds.

Everysport Media Group AB (publ.) assigns Erik Penser Bank as market maker and initiates collaboration on commissioned research

Everysport Media Group AB (publ.) (ESMG) has entered into an agreement with Erik Penser Bank (Erik Penser) giving Erik Penser the assignment to act as market maker for ESMG's share on Spotlight Stock Market. In connection with this, ESMG and Erik Penser have also initiated a collaboration on commissioned research.Erik Penser will do at least four analyzes per year, which will be published through Erik Penser Bank's distribution network. In addition, the analyzes will be published by ESMG through the company's usual publication channels, via press releases and on the company's website. In

NeoDynamics enters a scientific partnership to evaluate its technology platform in osteoarthritis

NeoDynamics AB (publ), (Spotlight Stockholm: NEOD), today announced that the Company joins in a research collaboration with the William Hunter Revisited research consortium to evaluate NeoNavia pulse biopsy system for joint tissue sampling in a new potential indication, osteoarthritis.The William Hunter Revisited research consortium consists of six universities and academic hospitals and is collaborating with industry to identify biomarkers and test new diagnostic devices for monitoring disease progression and repair as well as developing regenerative therapies for osteoarthritis. “We

First day of trading in warrants of series TO4 and TO5

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm, Denmark, November 12, 2020 – As previously communicated, ExpreS2ion Biotech Holding AB (publ) (“ExpreS2ion” or the “Company”) has issued 5,455,297 units in the recently completed rights issue (“the Offering”). One (1) unit

Transcendent Group subsidiary RegTech enters Lithuania

Transcendent Group, the Governance, Risk and Compliance experts, has announced that it has signed its first non-Swedish client within its subsidiary RegTech where it provides digital GRC services. The new client is a Lithuanian fintech company. Transcendent Group in Lithuania will provide services to the customer supporting the aim to strengthen its internal control framework (internal control and risk management procedures) using the RegTech tool Regulatory Framework Application (RFA). RFA was launched during 2019 and is used in Sweden by more than 20 clients. It is a subscription

ADDvise Group is updating financial target relating to EBITDA margin - Regulatory information

The board of directors in ADDvise Group has today, based on the strong result in the company, adopted a new EBITDA margin target. ADDvise’s previous EBITDA margin target was set at 10%. The new target is set at an EBITDA margin of 15%. In September 2017, when ADDvise adopted the previous EBITDA target of 10%, the EBITDA margin in the group as per Q3 2017, year to date, was at a level of 6.1%. As per Q3 2020, year to date, the EBITDA margin was at a level of 11.4%. - We have been working hard to improve the profitability in the group both by optimizing cost and by focusing on the

Invitation to presentation of Sectra’s six-month interim report on November 27

Linköping, Sweden – November 12, 2020 – The international medical imaging IT and cybersecurity company Sectra  (STO: SECT B) will publish its interim report for the period May to October 2020 on November 27. Sectra invites analysts, investors, and the media to attend a teleconference/audiocast in conjunction with the publication of the report.Publication of six-month interim report: 8:15 a.m. CET, November 27, 2020Presentation: 10:00 a.m. CET, November 27, 2020 To participate, follow online at investor.sectra.com/q2report2021 or call one of the following

Interim Financial report January – September 2020

Coming off the significant Covid-19 related revenue drop we experienced in our second quarter, LEAX third quarter revenue rebounded, specifically in September. After the seasonally slow summer period in July and August, which was exacerbated by Covid-19 effects, September showed us the first signs of pre-Covid-19 demand and the U-shaped recovery we have been expecting. Despite overall revenue still lagging Q3 2019 by greater than 20% our performance has improved by nearly 7% in EBITDA margin with Q3 2020 coming in at 11.3% versus a 4.6% EBITDA margin in Q3 2019. This improvement has been

Q1 Interim Report July – September 2020

Opening remarks The new fiscal year started well, with the actual transfer of funds from the European Union Horison 2020 grant, allowing Hamlet Pharma to strengthen its organization by recruiting financial and business development expertise, as well as experts in specific technology areas. The research team of scientists from leading international universities further ensures that the Company will reach important strategic goals. The clinical trials are being resumed, with permission from the Czech authorities. First, a dose-finding study will help to define the optimal dose for

Evolution launches world´s first online live Craps game

Evolution, leading provider of Live Casino solutions, has announced the launch of the world’s first ever online Live Craps game, set in an authentic underground, speakeasy-style studio.This unique online version of the legendary dice game stays true to the original while also taking full advantage of technology with its rich set of additional features, aimed to make the game easier to understand and play for both experienced and new players. Todd Haushalter, Chief Product Officer at Evolution, said: “Craps completes the Evolution portfolio in terms of offering every game you can find in

Viking Supply Ships AB (publ) Interim Report Q3 2020

As previous quarters, the financial net result for the third quarter was negatively impacted by low oil price and the COVID-19 situation, which has had a significant adverse effect on the global economic activity and outlook. Revenues for the third quarter was MSEK 100 (159), EBITDA was MSEK 2 (67), and the net result was MSEK -14 (33). Year-to-date, revenue was MSEK 230 (348), while EBITDA was MSEK -69 (51), and the net result was MSEK -146, down from MSEK -3 in the corresponding period in 2019. THIRD QUARTER · Total revenue was MSEK 100 (159) · EBITDA was MSEK 2 (67) ·

Cantargia publishes interim report for third quarter 2020

Cantargia AB’s (”Cantargia”) interim report for the period January until September 2020 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the third quarter · Positive interim results presented from phase 2a study CANFOUR on combination therapy with CAN04 and chemotherapy in patients with non-small cell lung cancer.     Significant events after the end of the period · The first patient started treatment with CAN04 in a phase I study in the US investigating CAN04 in combination with pembrolizumab. · Recruitment of

A strong recovery, and we’re ready for 2021

· EBITDA for the quarter was SEK 27.0 million, double the figure from the previous quarter and on a level with the corresponding quarter in the previous year.  · Pronounced increase in sales in key European markets, for example Germany and Sweden. Allgon has reorganised and adapted aspects of its sales operation in order to use digital channels to safeguard its sales and service functions.  · Continued preparations to enable the organisation to manoeuvre around any restrictions brought about by the pandemic. If a second wave impacts the market significantly, we will be ready for it. ·

Interim report January – September 2020

The period in summary Third quarter July 1 – September 30, 2020 · Our marketing authorization application for Strangvac was submitted to the European Medicines Agency, EMA, at the end of February. During the third quarter, we have strengthened the dossier in the areas where EMA has asked for clarification. We are happy to report that we remain on track with our schedule and plan for a positive statement from EMA during the first half of 2021. · We focus on the preparations for the launch of Strangvac, which includes a distribution partner for Europe, outside regions where we

Today is the first day of trading in DanCann Pharma A/S shares and warrants at Spotlight Stock Market

Today is the first day of trading in DanCann Pharma A/S ("DanCann Pharma") shares and warrants of series TO 1. DanCann Pharma’s shares are traded under the ticker "DANCAN" with ISIN DK0061410487 and DanCann Pharma’s warrants of series TO 1 are traded under the ticker "DANCAN TO 1" with ISIN DK0061410560.DanCann Pharma was provided approximately DKK 30 million (before issue costs) in the oversubscribed IPO of units which resulted in more than 1 600 new shareholders. The total number of shares in DanCann Pharma is 20 730 800 shares and the share capital amount to DKK 777 405. In addition,

Mentice publishes the company’s interim report for the period July–September 2020

Two exciting acquisitions and strong performance in the medical device industry segment  Third quarter (July–September 2020) · Net sales amounted to 33.4 (29.3) MSEK. · Operating income for the period before depreciations (EBITDA) totalled 4.1 (-6.7) MSEK. · Net income for the period amounted to -0.3 (-9.0) MSEK. · Earnings per share (EPS) was -0.01 (-0.37) SEK. · Order intake amounted to 34.6 (24.4) MSEK. · Cash flow from operating activities totalled -6.2 (-16.2) MSEK. First nine months of the year (January–September 2020) · Net sales for the first nine

Klaria announces regulatory approval of the pivotal bioequivalence clinical study with Sumatriptan Alginate Film

Klaria has successfully completed regulatory review and has secured all necessary approvals to start the pivotal bioequivalence study with Sumatriptan Alginate Film.   The Medicines and Healthcare products Regulatory Agency (MHRA) have granted their approval of the study.  Klaria will now initiate the clinical study and the company reiterated the previously communicated timelines for the study, confirming that results are expected in Q1, 2021.  Additionally, review of the comprehensive EU development plan with the Swedish Medical Products Agency (acting as representative of the European

Gasum opens the Turku biogas plant, the first in Finland to produce liquefied biogas ─ The circular economy becomes a reality in the Turku region

Gasum strives actively to increase biogas production capacity by expanding and improving the efficiency of existing biogas plants and by increasing biogas procurement. The opening of the Turku biogas plant took place today. The biogas plant is the first in Finland to produce liquefied biogas for transport, industrial and maritime needs.Start-up of Finland’s first biogas plant producing liquefied biogasThe major expansion and modernization of Gasum’s biogas plant in Topinoja, Turku has been completed. The plant was opened today, and commercial use of the plant started up. The expansion of

2020 Bulkers Ltd. (2020) – Commercial update and key information relating to the cash distribution for October 2020

Hamilton, Bermuda, November 12, 2020 Commercial update: In October 2020, the Company achieved average time charter equivalent earnings of approximately US$22,400 per day, gross. The Company’s two vessels trading on index-linked time charter earned approximately US$33,600 per day, gross, including average daily scrubber benefits of approximately US$1,300 per day. The Company’s six vessels trading on fixed time charter earned approximately US$18,700 per day, gross, including average daily scrubber benefits of approximately US$1,100 per day for three of the vessels. The Baltic 5TC

Ideagen Reveals Trading Since April Ahead of Last Year Despite Coronavirus and Makes Board Changes

· Trading update for six months to Oct 31, 2020 anticipates ARR (Annual Recurring Revenue) growth of 20% and adjusted EBITDA growth of 25% · Julian Clough joins Board as Non-Executive DirectorA global supplier of regulatory and compliance solutions, Ideagen Plc, has today released another very positive interim trading update. The trading update reveals that despite operating in a difficult global environment because of the coronavirus pandemic, Ideagen looks to have succeeded in increasing its ARR and adjusted EBITDA by 20% and 25% respectively. The ARR book (which is the

2020 Bulkers Ltd. (2020) - Results for the third quarter

Hamilton, Bermuda, November 12, 2020 2020 Bulkers Ltd (2020) (“2020 Bulkers” or the “Company”), today announced its unaudited financial and operating results for the three and nine months ended September 30, 2020. Key events during the third quarter of 2020 · The Company reported net profit of US$4.8 million and EBITDA of US$10.6 million for the third quarter of 2020. · Achieved average time charter equivalent earnings of approximately US$22,100, per day, gross. · In September 2020, the Company paid dividends of US$0.01 per share for the month of July, 2020. · In

Etrion Releases Third Quarter 2020 Results

November 12, 2020, Geneva, Switzerland – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), an  independent renewable power producer, released today its condensed consolidated interim financial statements and related management’s discussion and analysis (“MD&A”) for the three and nine months ended September 30, 2020. Q3-20 HIGHLIGHTS Operational · Etrion produced 17.0 Gigawatt-hours (“GWh”) of electricity from the Company’s 57-megawatt (“MW”) portfolio comprising 11 solar power plant sites in Japan. Production was in line with forecast but 7.2% below the same

WntResearch publishes quarterly report Q3 2020

The first part of the WntResearch Q3 report can be read in English below and the complete Swedish Q3 report is attached.THIRD QUARTER (JULY-SEPTEMBER 2020) · Operating income amounted to MSEK 0 (0) · Costs amounted to MSEK 5.2 (7.3) · The result before and after taxes amounted to MSEK -5.2 (-7.3) · Earnings per share amounted to SEK -0.10 (-0.29) THE FIRST NINE MONTHS OF THE YEAR(JANUARY-SEPTEMBER 2020) · Operating income amounted to MSEK 0 (0) · Costs amounted to MSEK 15.4 (17.1) · The result before and after taxes amounted to MSEK -15.4 (-17.1) · Earnings

There are no items matching the current filter
There are no more items matching the current filter
Back to top